Technology

Safe and induces an immune response

Phase 2 Randomized Controlled Trial of a Recombinant Adenovirus Type 5 Vector COVID-19 The vaccine (Ad5 vectorized COVID-19 vaccine) was carried out in China in April 2020 and involved more than 500 people. The main objective of the study was to assess the immune response and safety of the vaccine, …

Read More »